Estrella Immunopharma reports positive phase 1 data for cancer therapy Feb 9, 2026 07:01AM
Estrella Immunopharma (ESLA) Completes First Dose Cohort in STARLIGHT-1 Trial, Receives Approval to Initiate Higher Dose Cohort Feb 21, 2025 08:32AM
Estrella Immunopharma (ESLA) Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells Sep 27, 2024 12:00PM
Estrella Immunopharma (ESLA) Appoints Hong Zhang as Board Chair Aug 14, 2024 12:00PM